Скачать с ютуб Targeting Deubiquitinases for Therapeutic Benefit – 20 September 2022 в хорошем качестве

Targeting Deubiquitinases for Therapeutic Benefit – 20 September 2022

Co-opting the Ubiquitin/Proteasome System is an emerging therapeutic strategy, as demonstrated by Cereblon E3 Ligase Modifying Drugs (CELMoDs), Selective Estrogen Receptor Degraders (SERDs), and heterobifunctional degraders in the clinic. Deubiquitinases (DUBs) are a class of proteases that disassemble ubiquitin chains and remove ubiquitin moieties from target proteins. This webinar discusses strategies for targeting deubiqutinases, with an emphasis on achieving potency and specificity to achieve maximal therapeutic benefit.